SAFETY AND EFFICACY OF 24 WEEKS TREATMENT WITH ORAL TLR8 AGONIST, SELGANTOLIMOD, IN VIREMIC ADULT PATIENTS WITH CHRONIC HEPATITIS B: A PHASE 2 STUDY

被引：0
|
作者：
Janssen, Harry L. A. [1 ]
Lim, Young-Suk [2 ]
Kim, Hyung Joon [3 ]
Tseng, Cheng-Hao [4 ]
Coffin, Carla S. [5 ]
Elkhashab, Magdy [6 ]
Ahn, Sang Hoon [7 ]
Nguyen, Anh-Hoa [8 ]
Chen, Diana [8 ]
Wallin, Jeffrey [8 ]
Tan, Susanna [8 ]
Yang, Jenny C. [8 ]
Gagger, Anuj [8 ]
Brainard, Diana M. [8 ]
Fung, Scott K. [9 ]
Kim, Yoon Jun [10 ,11 ]
Kao, Jia-Horng [12 ]
Chuang, Wan-Long [13 ]
机构：
[1] Univ Hlth Network, Toronto Gen Hosp, Res Inst, Toronto Ctr Liver Dis, Toronto, ON, Canada
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Gastroenterol, Seoul, South Korea
[3] Chung Ang Univ, Coll Med, Seoul, South Korea
[4] E Da Hosp, Kaohsiung, Taiwan
[5] Univ Calgary, Gastroenterol & Hepatol, Calgary, AB, Canada
[6] Toronto Liver Ctr, Res, Toronto, ON, Canada
[7] Yonsei Univ, Coll Med, Gastroenterol, Severance Hosp, Seoul, South Korea
[8] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[9] Univ Toronto, Toronto, ON, Canada
[10] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[11] Seoul Natl Univ Hosp, Liver Res Inst, Seoul, South Korea
[12] Natl Taiwan Univ Hosp, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan
[13] Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung, Taiwan
来源：
HEPATOLOGY | 2020年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
829
引用
收藏
页码：506A / 507A
页数：2
相关论文
共 50 条
  • [41] Safety and efficacy of two-step peginterferon α-2a treatment in patients of chronic hepatitis B with acute exacerbation
    Chen, C. -C.
    Wang, P. -C.
    Chang, H. -W.
    Chen, C. -F.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2012, 19 (03) : 161 - 172
  • [42] 48 WEEKS SAFETY AND EFFICACY OF TENOFOVIR ALAFENAMIDE COMPARED TO TENOFOVIR DISOPROXIL FUMARATE AND ENTERCAVIR IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS B IN CHINA
    Zhang, Yeqiong
    Xu, Wenxiong
    Wang, Lu
    Wu, Lina
    Li, Jiangguo
    Xie, Chan
    Peng, Liang
    [J]. HEPATOLOGY, 2020, 72 : 474A - 475A
  • [43] Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies
    Zuckerman, Eli
    Gutierrez, Julio
    Ustianowski, Andrew
    Naggie, Susanna
    Caruntu, Florin Alexandru
    Ravendhran, Natarajan
    Sigal, Samuel
    Barrett, Lisa
    Cohen, Stanley
    Crown, Eric
    Dylla, Doug
    Fredrick, Linda
    Wang, Stanley
    Porcalla, Ariel
    Mensa, Federico
    Bruno, Savino
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E251 - E251
  • [44] EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR TREATMENT FOR 8 WEEKS IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS: ANALYSIS OF DATA POOLED FROM PHASE 2 AND 3 STUDIES
    Gutierrez, Julio
    Zuckerman, Eli
    Ustianowski, Andrew
    Naggie, Susanna
    Caruntu, Florin
    Ravendhran, Natarajan
    Sigal, Samuel
    Barrett, Lisa
    Cohen, Stanley M.
    Crown, Eric
    Dylla, Doug
    Fredrick, Linda
    Wang, Stanley
    Porcalla, Ariel R.
    Mensa, Federico
    Bruno, Savino
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : S1218 - S1218
  • [45] Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients (vol 24, pg 535, 2012)
    Buti, Maria
    Maria Morillas, Rosa
    Prieto, Martin
    Diago, Moises
    Perez, Juan
    Sola, Ricard
    Bonet, Lucia
    Palau, Antonio
    Testillano, Milagros
    Garcia-Samaniego, Javier
    Rodriguez, Manuel
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2012, 24 (08) : 999 - 999
  • [46] Treatment efficacy and safety of tenofovir disoproxil fumarate (TDF) in naive chronic hepatitis B for 144 weeks: a Real Life multicenter cohort study in Korea
    Song, Myeong Jun
    Jang, Jeong Won
    Bae, Si Hyun
    Yoon, Seung Kew
    Kim, Hee Yeon
    Kim, Chang Wook
    Song, Do Seon
    You, Chan Ran
    Lee, Sung Won
    Kwon, Jung Hyun
    Nam, Soon Woo
    Kim, Sang Gyune
    Kim, Young Seok
    Kim, Seok Hyun
    Lee, Byung Seok
    Cho, Eun-Young
    Lee, Hae Lim
    Lee, Tae-Hee
    [J]. HEPATOLOGY, 2017, 66 : 515A - 516A
  • [47] Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-naive non-cirrhotic patients with chronic hepatitis C virus Genotype 3 Infection
    Hezode, C.
    Leroy, V.
    Rosa, I.
    Roudot-Thoraval, F.
    Pawlotsky, J. -M.
    de Ledinghen, V.
    Bronowicki, J. -P.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S299 - S300
  • [48] Safety, tolerability and treatment effectiveness of chronic hepatitis B patients with pradefovir: a phase 1b multiple ascending dose study
    Jingrui, L.
    Junqi, N.
    Yanhua, D.
    Ning, X.
    Xiaoxue, Z.
    Xiaojiao, L.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S105 - S105
  • [49] EFFICACY AND SAFETY AFTER 64 WEEKS OF IXEKIZUMAB TREATMENT IN A PHASE 2 OPEN LABEL EXTENSION STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Genovese, M.
    Carlier, H.
    Erickson, J.
    Braun, D.
    Banerjee, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 616 - 616
  • [50] Efficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study
    Zhou, Jing
    Liu, Yue-Ying
    Lian, Jiang-Shan
    Pan, Li-Fang
    Yang, Jian-Le
    Huang, Jian-Rong
    [J]. CHINESE MEDICAL JOURNAL, 2017, 130 (08) : 914 - 919
12345